AI English summary of an SEC filing — figures as filed

The company said its board on November 13, 2024 elected Joseph Romanelli, 51, as an independent director and also appointed him to the Audit Committee, effective immediately.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Nov 13, 2024Period of report Nov 13, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said its board on November 13, 2024 elected Joseph Romanelli, 51, as an independent director and also appointed him to the Audit Committee, effective immediately.
Kimberly-Clark said the board size will increase from 12 to 13 directors in connection with Mr. Romanelli's appointment.
The company said Mr. Romanelli has been president of Human Health International at Merck & Co., Inc. since 2022, overseeing 75-plus markets outside the U.S. and leading a team of 14,000 colleagues. It said he previously served as chief executive of JiXing Pharmaceuticals and spent 25 years at MSD and Schering-Plough.
The company said Mr. Romanelli will participate in the outside director compensation programs described under “Director Compensation” in the proxy statement filed on March 11, 2024. Mike Hsu, chairman and chief executive officer, said Mr. Romanelli's global leadership experience and expertise will help the company advance its Powering Care strategy.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Joseph Romanelli Elected to Board

The company said its board on November 13, 2024 elected Joseph Romanelli, 51, as an independent director and also appointed him to the Audit Committee, effective immediately.

Source · Based on the filing body and exhibits

Board Size Increased from 12 to 13 Directors

Kimberly-Clark said the board size will increase from 12 to 13 directors in connection with Mr. Romanelli's appointment.

Source · Based on the filing body and exhibits

Mr. Romanelli's Background

The company said Mr. Romanelli has been president of Human Health International at Merck & Co., Inc. since 2022, overseeing 75-plus markets outside the U.S. and leading a team of 14,000 colleagues. It said he previously served as chief executive of JiXing Pharmaceuticals and spent 25 years at MSD and Schering-Plough.

Source · Based on the filing body and exhibits

Outside Director Pay and Hsu Comments

The company said Mr. Romanelli will participate in the outside director compensation programs described under “Director Compensation” in the proxy statement filed on March 11, 2024. Mike Hsu, chairman and chief executive officer, said Mr. Romanelli's global leadership experience and expertise will help the company advance its Powering Care strategy.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.